Phase 1 Trial

Oncorus Inc (NASDAQ: ONCR) shares slumped after the company reported initial data for its investigational cancer therapy ONCR-177 from a Phase 1 trial in heavily pretreated patients with advanced, injectable solid tumors. ONCR-177 is a Herpes Simplex Virus (HSV) product candidate. In the dose...

In a Phase I study across nine tumor types, Agenus Inc’s (NASDAQ: AGEN) CTLA-4 drug AGN1181 posted one complete response and three partial responses (PRs) as a monotherapy, according to data presented t SITC. The three responders expressed the low-affinity FcγRIIIA...

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects...

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) gave an update on its investigational Fabry disease treatment FLT190, currently in a Phase 1/2 trial, saying the candidate proved durable in the second patient tested. Fabry disease is an inherited metabolic disorder resulting from...

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported topline data from Phase 1b trial of its lead product candidate, YTX-7739, for mild-to-moderate Parkinson's disease. The study achieved its primary endpoints. YTX-7739 was shown to inhibit its primary target, stearoyl-CoA...

Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from a Phase 1 trial of TERN-501, a thyroid hormone receptor beta (THR-β) agonist, for NASH. TERN-501 was generally safe and well-tolerated in the SAD and MAD cohorts with a similar incidence of adverse events (...

Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154. The agreement was initially executed in 2017, under which Takeda had options for up to four molecules. Shattuck...

ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/gastroesophageal junction cancer patients receiving evorpacept plus Roche Holdings AG's (OTC: RHHBY) Herceptin (...

In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib plus Merck & Co Inc’s (NYSE: MRK) Keytruda (pembrolizumab) in KRAS-mutated first-line non-small cell...

MorphoSys AG (NASDAQ: MOR) presented interim results from the M-PLACE Phase 1b/2a study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN). Felzartamab is a fully human IgG1 monoclonal anti-CD38 antibody that can potentially deplete CD38-positive...

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease.  As of the September 17, 2021 cutoff date, results from the four patients treated in...

Moderna Inc (NASDAQ: MRNA) has quietly announced the discontinuation of an mRNA program for the chikungunya virus. The Company is scrapping Phase 2 plans for mRNA-1944, the antibody directed at the chikungunya virus.  Moderna did not provide a reason for the decision, saying...

Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were presented at the American College of Rheumatology (ACR) annual meeting.  The data showed that itolizumab...

Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials...

Cabaletta Bio Inc (NASDAQ: CABA) has announced 28-day clinical data from the third dose cohort (500 million DSG3-CAART cells) in the DesCAARTes Phase 1 trial for mucosal-dominant pemphigus vulgaris (mPV). The Company observed a dose-dependent increase in DSG3-CAART persistence in...